ibrutinib (imbruvica) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ibrutinib is an orally bioavailable Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of mantle cell lymphoma (MCL) patients that previously received at least one therapy. The drug was jointly developed by Janssen Biotech and Pharmacyclics. Ibrutinib selectively binds to Cys-481 residue in the allosteric inhibitory segment of BTK (TK/SH1 domain), and irreversibly blocks its enzymatic activity thus preventing B-cell activation and signaling, totally blocking the B-cell receptor and cytokine receptor pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. Apart from mantle cell lymphoma Ibrutinib is approved for the treatment of chronic lymphocytic leukemia and Waldenstrom Macroglobulinemia.   NCATS

Chemistry

  • SMILES: NC1=C2C(=NC=N1)N(N=C2C3=CC=C(OC4=CC=CC=C4)C=C3)[C@@H]5CCCN(C5)C(=O)C=C
  • InChIKey: XYFPWWZEPKGCCK-GOSISDBHSA-N
  • Mol. Mass: 440.4971
  • ALogP: 4.22
  • ChEMBL Molecule:
    ibrutinib  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$74.7208 - $74.8374

United States

$103.4157 - $405.9757
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one | cra-032765 | ibrutinib | imbruvica | pci32765 | pci 32765 | pci-32765 | pci-32765-00

Organizations (157)

Research & Development (153)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (94)

Approved Indications (3)


 

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Mantle-Cell

Waldenstrom Macroglobulinemia

Experimental Indications - Clinical Trial Phases 1-4 (94)


 

Agammaglobulinaemia Tyrosine Kinase (Phase 2/Phase 3)

Amyloidosis (Phase 2)

Anemia (Phase 3)

Anemia, Aplastic (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Anemia, Refractory (Phase 2)

Antigens, CD20 (Phase 2)

Body Weight (Phase 2)

Bone Marrow Failure Disorders (Phase 2)

Breast Neoplasms (Phase 1/Phase 2)

Burkitt Lymphoma (Phase 2)

Carcinoid Tumor (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 1/Phase 2)

Carcinoma, Transitional Cell (Phase 1/Phase 2)

Central Nervous System Neoplasms (Phase 1/Phase 2)

Chromosome Aberrations (Phase 2)

Colonic Diseases (Phase 1/Phase 2)

Colonic Neoplasms (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 1/Phase 2)

COVID-19 (Phase 2)

Cyclin D1 (Phase 2)

Cyclin D2 (Phase 2)

Cyclin D3 (Phase 2)

Drugs, Investigational (Phase 2)

Ependymoma (Phase 1)

Esophageal Neoplasms (Phase 2)

Fever (Phase 2)

Food (Phase 2)

Food Hypersensitivity (Phase 2)

Glioblastoma (Phase 1)

Graft vs Host Disease (Phase 4)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1/Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 2)

Hepatitis B, Chronic (Phase 3)

HIV Infections (Phase 1)

Hodgkin Disease (Phase 2)

Hyperplasia (Phase 1)

Immunoglobulin Light Chains (Phase 2)

Infections (Phase 2)

Intestinal Neoplasms (Phase 1)

Intraocular Lymphoma (Phase 2)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 4)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Hairy Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell ()

Leukemia, Lymphoid (Phase 3)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, Mast-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Acute (Phase 2/Phase 3)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Prolymphocytic (Phase 2)

Leukemia, Prolymphocytic, B-Cell (Phase 1)

Leukemia, Prolymphocytic, T-Cell (Phase 2)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 1/Phase 2)

Lymphoma (Phase 3)

Lymphoma, AIDS-Related (Phase 1)

Lymphoma, B-Cell (Phase 4)

Lymphoma, B-Cell, Marginal Zone (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell ()

Lymphoma, Non-Hodgkin (Phase 4)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Lymphoma, T-Cell (Phase 1)

Lymphomatoid Granulomatosis (Phase 1)

Mastocytosis, Systemic (Phase 2)

Medulloblastoma (Phase 1)

Melanoma (Phase 2)

Monoclonal Gammopathy of Undetermined Significance (Phase 2)

Multiple Myeloma (Phase 2)

Mutation (Phase 2/Phase 3)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms ()

Neuroectodermal Tumors (Phase 1)

Pancreatic Neoplasms (Phase 2/Phase 3)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 1/Phase 2)

Recurrence (Phase 2)

Risk Factors (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Squamous Intraepithelial Lesions (Phase 1/Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Testicular Neoplasms (Phase 1)

Waldenstrom Macroglobulinemia ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 321
  • # of Trial Organizations: 153

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue